FleetPulse | $11,000,000 | (May 10, 2024)
ArkeaBio™ | $26,500,000 | (May 10, 2024)
Bluejay Therapeutics | $182,000,000 | (May 10, 2024)
Certified by Founder
Lodge
Loyal / Cellular Longevity
start up
United States
- San Francisco, CA
- 22/03/2024
- Series B
- $45,000,000
Loyal is part of Cellular Longevity, a company working to develop the first drugs explicitly intended to extend healthspan and lifespan — first in dogs, and then in humans, too.
By quantifying and controlling the mechanisms of aging, we hope to delay the onset and reduce the severity of age-related diseases, which means more, healthier years for both species.
At Loyal, our first products to market are focused on longevity and healthspan in dogs. Join us in our mission to help dogs everywhere.
- Industry Biotechnology Research
- Website https://loyalfordogs.com/
- LinkedIn https://www.linkedin.com/company/loyalfordogs/
Related People
Celine HaliouaFounder
United States -
San Francisco, California
Interested in: the biology of aging, the impact of healthcare inequality, economics of novel therapeutics, early-stage biotech venture capital. www.celinehh.com
CoverTree | $13,000,000 | (May 10, 2024)
Li Industries | $36,000,000 | (May 10, 2024)
Archive Intel | $1,000,000 | (May 10, 2024)
Little Sparrows Technologies | $3,000,000 | (May 10, 2024)
Triomics | $15,000,000 | (May 10, 2024)
Altera | $9,000,000 | (May 10, 2024)
Electricity Maps | $5,390,775 | (May 10, 2024)
Sift Healthcare | $20,000,000 | (May 10, 2024)
Aardvark Therapeutics | $85,000,000 | (May 10, 2024)
Chip City | $7,500,000 | (May 10, 2024)